Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock Has Consensus Price Target of $8.18 According to Brokerages

Key Points

• Analyst sentiment is mixed: Five firms give Recursion Pharmaceuticals a consensus “Hold” rating—two Buy, two Hold and one Sell—with an average 12-month price target of $8.18.
• RXRX shares traded at $3.52, while the company reported quarterly EPS of -$0.22, matching estimates, and revenue of $18.55 million, above the $14.81 million consensus.
• Company insiders sold 167,408 shares worth about $701,000 over the past 90 days; the CEO’s and director’s sales were made under pre-arranged trading plans.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) has earned a consensus recommendation of "Hold" from the five research firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and two have issued a buy recommendation on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $8.18.

Several research firms recently commented on RXRX. Morgan Stanley set a $5.90 price target on shares of Recursion Pharmaceuticals in a research report on Friday, October 16th. Weiss Ratings reissued a "sell (d-)" rating on shares of Recursion Pharmaceuticals in a research report on Thursday, October 15th. Wall Street Zen upgraded shares of Recursion Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $8.00 target price on shares of Recursion Pharmaceuticals in a report on Monday, October 19th.

Recursion Pharmaceuticals Stock Up 0.6%

Shares of NASDAQ RXRX traded up $0.02 during mid-day trading on Friday, reaching $3.52. The company had a trading volume of 15,546,436 shares, compared to its average volume of 29,299,366. The firm has a 50 day simple moving average of $3.77 and a two-hundred day simple moving average of $3.52. Recursion Pharmaceuticals has a 52-week low of $2.77 and a 52-week high of $5.24. The company has a current ratio of 5.03, a quick ratio of 5.03 and a debt-to-equity ratio of 0.01. The stock has a market cap of $1.88 billion, a P/E ratio of -3.91 and a beta of 1.15.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings results on Monday, November 2nd. The company reported ($0.22) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.22). The firm had revenue of $18.55 million for the quarter, compared to the consensus estimate of $14.81 million. Recursion Pharmaceuticals had a negative return on equity of 46.47% and a negative net margin of 697.15%. During the same quarter last year, the business posted ($0.36) EPS. Sell-side analysts predict that Recursion Pharmaceuticals will post -0.89 earnings per share for the current year.

Insider Buying and Selling at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, CEO Najat Khan sold 22,408 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $3.52, for a total value of $78,876.16. Following the transaction, the chief executive officer directly owned 2,072,890 shares in the company, valued at approximately $7,296,572.80. This trade represents a 1.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Robert Hershberg sold 25,000 shares of the stock in a transaction on Tuesday, October 6th. The stock was sold at an average price of $5.00, for a total value of $125,000.00. Following the sale, the director directly owned 162,156 shares of the company's stock, valued at approximately $810,780. This represents a 13.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 167,408 shares of company stock valued at $701,276 in the last ninety days. Insiders own 6.65% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC purchased a new position in shares of Recursion Pharmaceuticals during the 1st quarter worth approximately $7,370,000. Hsbc Holdings PLC boosted its stake in shares of Recursion Pharmaceuticals by 537.3% in the fourth quarter. Hsbc Holdings PLC now owns 818,316 shares of the company's stock valued at $3,367,000 after buying an additional 689,903 shares in the last quarter. Bank of America Corp DE boosted its stake in shares of Recursion Pharmaceuticals by 18.2% in the first quarter. Bank of America Corp DE now owns 2,496,831 shares of the company's stock valued at $7,665,000 after buying an additional 384,486 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Recursion Pharmaceuticals by 29.3% in the first quarter. Bank of New York Mellon Corp now owns 1,462,631 shares of the company's stock valued at $4,490,000 after buying an additional 331,048 shares in the last quarter. Finally, First Trust Advisors LP grew its holdings in Recursion Pharmaceuticals by 15.2% during the first quarter. First Trust Advisors LP now owns 2,610,726 shares of the company's stock worth $8,015,000 after acquiring an additional 344,035 shares during the period. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc is a biotechnology company that uses advanced computing, artificial intelligence and automated biology to discover and develop new medicines. The company's platform, known as the Recursion Operating System, combines large-scale biological experimentation with machine learning and data analysis to identify potential drug candidates and characterize how diseases respond to treatments.

Recursion applies its technology to a range of therapeutic areas, including oncology, rare diseases, neuroscience and infectious diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.